Sphingosine 1-phosphate attenuates MMP2 and MMP9 in human anaplastic thyroid cancer C643 cells: Importance of S1P2

Muhammad Yasir Asghar1,2, Kati Kemppainen1, Taru Lassila1, Kid Törnquist1,2*

1 Cell Biology, Faculty of Science and Engineering, Abo Akademi University, BioCity, Artillerigatan, Turku, Finland, 2 The Minerva Foundation Institute for Medical Research, Biomedicum Helsinki, Helsinki, Finland

* ktornqvi@abo.fi

Abstract

In anaplastic thyroid cancer C643 cells, sphingosine 1-phosphate (S1P) attenuates migration by activating the S1P2 receptor and the Rho-ROCK pathway. In the present study, we show that stimulating C643 cells with S1P decreases the expression, secretion and activity of matrix metalloproteinase-2 (MMP2), and to a lesser extent MMP9. Using receptor-specific antagonists, and S1P2 siRNA, we showed that the inhibition of expression of MMP2 is mediated through S1P2. Furthermore, S1P inhibited calpain activity, and inhibiting calpain pharmacologically, inhibited the effect of S1P on MMP2 expression and activity, and on MMP9 activity. S1P treatment increased Rho activity, and by incubating cells with the Rho inhibitor C3 transferase or the ROCK inhibitor Y27632, the S1P-induced inhibition of invasion and MMP2 expression and activity was abolished. We conclude that S1P attenuates the invasion of C643 cells by activating S1P2 and the Rho-ROCK pathway, by decreasing calpain activity, and by decreasing the expression, secretion and activity of MMP2 and, to a lesser extent, MMP9. Our results thus unveil a novel function for the S1P2 receptor in attenuating thyroid cancer cell invasion.

Introduction

Sphingosine 1-phosphate (S1P), a bioactive lipid, is a regulator of many cellular processes, including cancer cell invasion and migration [1]. S1P can bind to five G-protein coupled receptors (S1P1–5), which activate downstream signaling pathways [2]. In many cancer cells, including follicular thyroid cancer ML-1 cells, S1P promotes migration and invasion by activating S1P1–3 and downstream PI3K-Akt and Rac signaling pathways [3–8]. However, S1P inhibits migration and invasion by activating S1P receptor 2 and the downstream Rho-ROCK signaling pathway and by inhibiting Rac activity in many cell types [9], including human anaplastic thyroid cancer C643 cells [10]. In some cell types, however, S1P2 can also enhance migration [11]. The small GTP-ase Rac promotes invasion [12] and has been shown to regulate S1P-evoked matrix metalloproteinase 2 and -9 (MMP2 and -9) secretion in cancer cells [13]. The MMPs are zinc-dependent proteolytic enzymes, which are expressed and secreted into the...
extracellular matrix by cancer cells [14]. The inactive zymogen forms of MMP2 and MMP9 are activated by calpains (calcium-dependent proteolytic enzymes), which cleave the pro-peptide domains. MMP2 and MMP9 use mainly collagen IV as substrate and digest the basement membrane to promote cell invasion in cancer cells [13,15–18].

Previous studies show that increased expression and activity of MMP2 and MMP9 in thyroid cancer cells promotes invasion [18]. Recently, we have reported that S1P induces secretion and activity of MMP2 and MMP9 through S1PR1,3, and that these MMPs are important for the S1P-evoked invasion of thyroid cancer ML-1 cells [19]. However, the role of MMP2 and MMP9 in S1P-evoked inhibition of invasion of thyroid cancer cells remained unknown. In the present study, we have investigated the expression, secretion and activity of MMP2 and MMP9 in thyroid cancer C643 cells where S1P inhibits invasion. Our results show for the first time that S1P can attenuate the expression, secretion and activity of MMP2 and MMP9. This occurs via a S1P2-evoked activation of the Rho-ROCK pathway, and an inhibition of calpain activity. We propose that S1P-evoked inhibition of invasion is mediated, at least in part, by effects on MMP2 and MMP9.

Materials and methods

DMEM, BSA, fatty acid-free BSA (FAF-BSA), Mitomycin C, ethidium bromide, SB-3CT and JumpStart Taq DNA polymerase were purchased from Sigma Aldrich Corporation (St. Louis, MO, USA). RPMI 1640 medium was from Lonza (Basel, Switzerland). S1P was purchased from Biomol (Plymouth, PA, USA). FBS, penicillin/streptomycin (P/S), L-Glutamine, trypsin, F-12 Ham’s nutrient medium and OptiMEM were from Gibco Life Technologies (Grand Island, NY, USA). Primary antibodies against S1P2 and S1P3 were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). HRP-conjugated goat anti-rabbit IgG was purchased from Bio-Rad Laboratories (Hercules, CA, USA). MMP2 and anti-mouse IgG antibodies were from Cell Signaling Technology (Denver, MA, USA). MMP9, S1P1, S1P4, S1P5 antibodies and the calpain activity assay kit were purchased from Abcam (Cambridge, MA, USA). Human collagen type IV and cell culture plastic-ware were from Becton Dickinson (Bedford, MA, USA). Transwell migration inserts were from Corning, Inc. (Corning, NY, USA). The bicinchoninic acid protein assay reagent kit was from Pierce. All the chemicals and reagents used were of molecular biology and reagent grades. JTE-013 was from Tocris Biosciences (Ellisville, MO, USA). VPC23019 was purchased from Avanti Polar Lipids (Alabaster, AL, USA). Y27632 was obtained from Calbiochem (San Diego, CA, USA). C3 Transferase was from Cytoskeleton, Inc. (Denver, CO, USA). MMP2 siRNA “ACAAGAACCAGAUCACAUA” and MMP9 siRNA “GCAUAAGGACGACGUGAAU” were ON-TARGET SMART pool siRNA from Dharmacon (Lafayette, CO, USA). Nitrocellulose transfer membrane was from Whatman (Maidstone, UK). The western lightning Plus-ECL kit was from Perkin Elmer (Whatman, MA, USA).

Cell culture

The human anaplastic thyroid cancer C643 cells were provided by Dr. Nils-Erik Heldin (Karolinska Institute, Stockholm, Sweden). The cells were grown in DMEM supplemented with 10% FBS, 1% P/S and 2 mM L-glutamine. The human follicular thyroid cancer FTC-133 cells were obtained from Banca Biologica e Cell Factory, National Institute of Cancer Research (Genova, Italy). The cells were cultured in DMEM and F12 (Ham’s nutrient) medium (1:1) supplemented with 10% FBS, 1% P/S and 2 mM L-glutamine. Both C643 and FTC-133 thyroid cancer cell lines used in this study are verified unique thyroid cancer cell lines [20]. The cell cultures were maintained in a water-saturated atmosphere with 5% CO2 at 37°C.
End-point PCR and quantitative real-time PCR (qPCR)

RNA was extracted with TRI Reagent (Sigma Aldrich; St Louis, MO) and Aurum™ Total RNA Mini Kit (Bio-Rad; CA, USA) according to the manufacturer’s instructions. RNA integrity was checked by gel electrophoresis and RNA concentration and purity was determined with Nanodrop 2000 (Thermo Fisher Scientific; Waltham, MA) and NanoVue Plus (Healthcare Bio-Sciences AB; Uppsala, SE). cDNA samples were prepared with RevertAid reverse transcriptase and SuperScript IV ™ Reverse Transcriptase Invitrogen (Thermo Fisher Scientific, MA, USA) from equal amounts of RNA. For MMP9 qPCR experiments on FTC-133 RNA samples, the cDNA was made by using MMP9 gene specific primer instead of random hexamers.

End-point PCR- The reaction mixtures for S1P1-5 were prepared with JumpStart™ Taq polymerase according to the manufacturer’s instructions (Sigma-Aldrich, MO, USA). Reaction mixtures without the reverse transcriptase enzyme RNA controls (RNA C) and Non-template controls (NTC) were used to ensure that RNA preparations and PCR mixtures were not contaminated. RT-PCR were performed with Mastercycler gradient (Eppendorff, Hamburg, Germany). Human hypoxanthine phosphoribosyl transferase (HPRT) was used as a reference gene. The information about primers sequences and the PCR cycling settings are mentioned in the Table 1.

Quantitative real-time PCR (qPCR)—Real-time PCR assays for MMP2 and MMP9 were designed with the Universal Probe Library (UPL) Assay Design Center (www.rocheappliedscience.com). MMP2 and MMP9 primers were purchased from TAG Copenhagen (Copenhagen, Denmark) and UPL probes from Roche (Basel, Switzerland). MMP primers and the probe for the reference gene GAPDH were from Oligomer (Helsinki, Finland). For MMP2 qPCR, reaction mixtures were prepared with KAPA Probe Fast Master Mix (KAPA Biosystems; Boston, MA) and qRT-PCR was performed with the StepOnePlus Real-Time PCR System (Applied Biosystems; Waltham, MA) using the relative standard curve method. The

Table 1. PCR primers, probes and cycling conditions.

| Gene  | Primer Sequence | Probe | Amplicon | MgCl2, mM | Anneling T °C | Melting Temp (°C) |
|-------|-----------------|-------|----------|-----------|---------------|------------------|
| MMP2  | for 5’-ataaaccttgatgcgccgctg-3’ | UPL #70 | 63 nt | 2 | 60 | 95 |
|       | rev 5’-agccaccccttggaagagtgc-3’ |       |       |       |       |       |
| MMP9  | for 5’-atccggcacacctctatggtc-3’ | UPL #43,#6 | 121 nt | 2 | 60 | 95 |
|       | rev 5’-ctgaggggtggacagcgtg-3’ |       |       |       |       |       |
| S1P1  | for 5’-ggtctggaactgcatcgtg-3’ |       | 223 bp | 4 | 60 | 89–90 |
|       | rev 5’-gacgcagcgcacatctcatcagacg-3’ | | | | | |
| S1P2  | for 5’-ccgaaaacagcagttcaccct-3’ |       | 197 bp | 2 | 61 | 90 |
|       | rev 5’-ccaggaggctgaagacagag-3’ | | | | | |
| S1P3  | for 5’-aaggtcagtgtctcatcgt-3’ |       | 201bp | 2 | 61 | 92–93 |
|       | rev 5’-gctatgttgtgtctgtgcttg-3’ | | | | | |
| S1P4  | for 5’-cttccagcctgtctttcact-3’ |       | 223 bp | 2 | 64 | 94 |
|       | rev 5’-aagagcagtgtcgcggtgga-3’ | | | | | |
| S1P5  | for 5’-aggactttccgcttttgcttg-3’ |       | 201bp | 3 | 59 | 87 |
|       | rev 5’-tctagactccaccggtcctg-3’ | | | | | |
| PBGD  | for 5’-cccaacgccgacacgccttg-3’ |       | 204 bp | 3 | 62 | 89 |
|       | rev 5’-agaatcttctccccttggtgga-3’ | | | | | |
| GAPDH | for 5’-gcttcagcagctgcccgac-3’ | 5’- accaggcggcacaagcacacaa -3’ | 229 nt | 2 | 60 | 95 |
|       | rev 5’-gaattttgcacatggctgga-3’ | | | | | |
| HPRT  | for 5’-tgttaatagacgcaactcaaacaggg-3’ |       | 2 | 60 | 94 |
|       | rev 5’-tgctctatatccaaacacttcg-3’ | | | | | |
MMP9 qPCR reaction mixtures for FTC-133 cells were prepared with PowerUp™ SYBR™ Green Master Mix according to the manufacturer’s instructions (Applied biosystems, Thermo Fisher Scientific, MA, USA) and qRT-PCR was performed with the StepOnePlus Real-Time PCR System (Applied Biosystems; Waltham, MA) using the relative standard curve method. For MMP9, porphobilinogen deaminase (PBGD) and for MMP2, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as reference genes.

**Transient transfections**

4,000,000 cells were pelleted and suspended in 200 µl OptiMem. siRNA (2 µM) was suspended in 200 µl OptiMem. The two suspensions were mixed, incubated for 15 min at room temperature and transferred into an electroporation cuvette (0.4 cm). The cells were electroporated at 240 V and 500 μF. The electroporated cells were transferred to 100-mm cell culture plates and used in experiments 48 h after transfection. A non-targeting siRNA was used as negative control.

**Invasion assays**

Invasion assays were performed as described elsewhere [10]. Cells were grown in 0.2% FAF-BSA-containing serum-free medium (SFM) overnight before the start of an experiment. In some experiments, cells were pre-incubated with JTE-013 (10 µM, 1 h), VPC 23019 (1 µM, 1 h), C3-Transferase (100 ng/ml, 4 h), Y-27632 (10 µM, 1 h), SB-3CT (10 µM, 1 h) or ALLN (50 µM, 1 h). The inhibitors were present in both the upper and lower chambers throughout the experiment. The cells were stimulated with S1P and allowed to migrate towards 5% lipid-stripped FBS (LS-FBS) for the time points indicated and then non-migrated cells were removed with a cotton swab. The migrated cells were fixed in 2% paraformaldehyde for 10 min and then stained with 0.1% crystal violet in 20% methanol for 5 min. The membranes were washed with PBS and water and allowed to dry overnight. The cells were counted at 40X magnification in eight to ten fields in a straight line bisecting the membrane. Images of invasion inserts were captured using Leica EC3 camera (Leica Microsystems, Switzerland Ltd., CH, Switzerland) and with 20X magnification objective on Leica microscope (Leica Microsystems CMS GmbH, Wetzlar, Germany).

**Wound healing assays**

Cell were grown to 90% confluency. On the day prior to an experiment, the medium was changed to SFM. The next day, fresh SFM was added to the plates. 0.5 µg/ml mitomycin C was added to each plate to inhibit cell proliferation. The monolayer of cells was scratched with a micropipette tip (200 µL). The cells were treated with 100 nM S1P while vehicle was added in the control plates. The images were taken immediately (0 h) and after 24 h with a Leica microscope camera and framework software (Leica Microsystems; Wetzlar, Germany). The distance traveled by the cells to close the wound was measured. The data is presented as % wound.

**Zymography assays**

Cells were grown on 35-mm plates to 90% confluency. The medium was changed to SFM overnight. The next day, fresh SFM was added to the plates and the cells were stimulated with S1P or vehicle. After 6 h, the medium was collected from each plate. Equal volumes of medium were mixed with loading buffer (0.1 M Tris-phosphate buffer, pH 6.8, containing 20% glycerol, 6% SDS, and 0.04% bromophenol blue). The samples were electrophoresed with 10% SDS gels containing gelatin (2.65 mg/ml). Next, the gels were incubated in Zymo buffer (50 mM Tris-HCl containing 2.5% Tween 80 and 0.02% NaN₃, pH 7.5) for 30 min. The gels were then
incubated in Zymo I buffer containing 1 μM ZnCl$_2$ and 5 mM CaCl$_2$ for 30 min. For gelatinolytic activity, gels were incubated at 37°C overnight in buffer containing 50 mM Tris-HCl, 5 mM CaCl$_2$, 1 μM ZnCl$_2$, and 0.02% NaN$_3$ (pH 7.5). The gels were visualized under UV light for protein ladder marker and after that the gels were stained with Coomassie Blue R250 for 1–2 h. The gelatinolytic activity was visualized as clear bands against blue background on stained gels. The bands were quantified with the Image J program. The data were normalized with the respective total protein concentrations of the cells on the culture plates.

**Western blotting**

The cells were grown to 90% confluency. The medium was changed to SFM overnight. On the day of the experiment, fresh SFM was added to the plates and the cells were stimulated with S1P for 6 h. In some experiments, the cells were pre-incubated with the S1P$_2$ inhibitor JTE—013 (10 μM, 1 h), the S1P$_{1,3}$ inhibitor VPC—23019 (1μM, 1 h), MMP2/9 inhibitor SB-3CT (10 μM, 1 h), calpain inhibitor ALLN (50 μM, 1 h), the ROCK inhibitor Y27632 (10 μM, 1 h) or with Rho inhibitor C3-transferase (100 ng/ml, 4 h). After collection of medium for secretion experiments, the cells were washed with ice cold PBS and lysed in lysis buffer (10 mM Tris, pH 7.7, 150 mM NaCl, 7 mM EDTA, 0.5% NP-40). Cell lysates were centrifuged at 13,000 rpm for 15 min at 4°C. The supernatants were collected and their protein concentration was measured with a BCA protein assay kit. Laemmli sample buffer was added to all samples and western blotting was performed as described previously [6]. The primary antibodies used were anti-MMP2 (1:500), anti-MMP9 (1:500), Hsc70 (1:5000) and β-actin (1:1000). The secondary antibodies used were peroxide-conjugated goat anti-rabbit (1:3000), anti-mouse (1:3000) and anti-rat (1:3000). β-actin and Hsc70 were used as loading control in MMP and S1P receptor expression experiments. However, in MMP secretion experiments, the amounts of secreted MMPs were normalized against total protein concentrations of the cells on the plates.

**Calpain activity assays**

2 000,000 cells were grown on 100-mm plates. The cells were serum-starved overnight and treated with 100 nM S1P for 6 h. The cells were detached and washed three times with PBS. Thereafter, calpain activity assays were processed according to the manufacturer’s instructions. Fluorescence was measured using a Hidex sense microplate reader instrument (HIDEX Corp, Turku, Finland) with excitation at 400 nm and emission at 505 nm. The protein concentration was kept at 60 mg/ml for each sample.

**Rho activation assays**

50,000 cells were plated on 35-mm plates, grown until they reached 50% confluency, and then serum-starved for 24 h. The cells were treated with 100 nM S1P for 0, 1, 3, 6 and 12 min and the lysates were made, aliquoted for protein concentration measurement, snap-frozen immediately after harvesting and clarified as directed in the user’s manual. Protein concentration was measured using the BCA kit. The protein concentration used for assays was kept at 0.5 mg/ml in each sample. Rho activation was measured with the G-LISA™ Rho activation assay kit (Cytoskeleton, Inc.; Denver, CO, USA) according to the manufacturer’s instructions.

**Statistics**

Results are presented as mean ± SEM from at least three independent measurements. Student’s $t$-test was applied to the data when two means were compared. One-way ANOVA and
Bonferroni’s *post hoc* test was used when three or more means were compared. The GraphPad Prism 5 software (GraphPad Software Inc.; San Diego, CA) was used for the statistical analyses. P-values < 0.05 were considered statistically significant.

**Results**

**S1P inhibits expression, secretion and activity of MMP2 and MMP9 in C643 cells**

Previously, we have shown that S1P (100 nM, 6 h) inhibits migration and invasion of human anaplastic thyroid cancer C643 and follicular thyroid cancer FTC-133 cells towards lipid-stripped serum. This attenuated migration is mediated by S1P$_2$ and the Rho-ROCK pathway.
Interestingly, S1P promotes migration and invasion in human follicular thyroid cancer ML-1 cells and increases the secretion and activity of MMP2 and MMP9 through S1P1,3 [19]. This effect on MMP2/9, at least in part, mediates S1P-evoked invasion of these cells [19]. As can be seen in (Fig 1A and 1B): S1P1,3 and S1P5 are expressed in C643 and FTC-133 cells. Furthermore, neither of these cell line expressed S1P4. Despite the same S1P receptor expression profile, S1P promotes migration in ML-1 cells and inhibits migration in C643 and FTC-133 cells.

In the present study, we have investigated the role of MMP2 and MMP9 in C643 cells. Our results show for the first time that stimulation with S1P decreased expression, secretion, and activity of MMP2 at 2 h, 4 h, 6 h and 8 h (Fig 2A, 2C and 2D). Stimulation with S1P also decreased the expression of MMP9 at 2 h and 4 h, secretion at 4 h and activity at 2 h, 4 h, and 6 h (Fig 2A, 2C and 2D). Interestingly, S1P significantly increased the expression, but not the secretion, of MMP9 at 6 h (Fig 2A and 2C). We next determined the effect of S1P on MMP2 and MMP9 mRNA expression after 2 h, 4 h, 6 h and 8 h of S1P treatment, and as can be seen in Fig 2B, S1P significantly decreased MMP2 mRNA expression at 4 h but no effect was observed in other time points. S1P had no effect on MMP9 mRNA expression at 2 h and 4 h but caused a marked increase in MMP9 mRNA at 6 h and 8 h.

To correlate the S1P-evoked response on MMP2 and -9 with the invasion of C643, we measured the effect of short S1P stimulations on C643 invasion. Our results show that S1P potently attenuates invasion at 2 h, 4 h, 6 h, and 8 h of stimulation (Fig 2E). In addition, S1P also decreased the expression, secretion and activity of MMP2 at 6 h and 8 h in thyroid follicular cancer FTC-133 cells (Fig 3A, 3B and 3C). Furthermore, at these time points, S1P potently attenuated the invasion of these cells (Fig 3D). However, S1P, has no effect on MMP2 mRNA expression in 6 h and 8h but significantly increased MMP9 mRNA at 8h (Fig 3E). We observed the same biphasic response of S1P on MMP9 in these cells as we observed in C643 cells: after 6 h of incubation, S1P decreased the expression and secretion of MMP9, whereas at 8 h of incubation, the expression, but not the secretion, was increased. However, S1P decreased the activity of MMP9 at both 6 h and 8 h (Fig 3C).

S1P-induced inhibition of expression, secretion and activity of MMP2 is mediated by S1P2

Previously, we have shown that C643 cells express S1P1,3 [10]. First, we investigated the effect of S1P on the invasion of C643 cells. In C643 cells pre-treated with the S1P1,3 antagonist VPC-23019 (1 μM, 1 h) or the S1P2-antagonist JTE-013 (10 μM, 1 h), and then stimulated with S1P for 6 h, showed that the S1P-evoked inhibition of C643 invasion was mediated by S1P2 and not by S1P1,3 (Fig 4A), as was also shown previously [10]. We next investigated which S1P receptor was involved in the S1P-induced attenuation of the expression, secretion and activity of MMP2 and -9. For this, the C643 cells were again pre-incubated with either VPC-23019 or JTE-013 and then stimulated with S1P for 6 h. The results showed that the S1P-induced inhibition of expression, secretion and activity of MMP2 was mediated by S1P2.
S1P attenuates MMP2 and -9

A

B

C

D

E

Relative MMP9 Expression

Relative MMP9 Secretion

Relative MMP9 Activity

% invasion

MMP2 / GAPDH

MMP9 / PBGD

C 6h

S1P 6h

C 8h

S1P 8h

6h

8h

6h

8h

6h

8h

6h

8h
inhibition of MMP2 expression and secretion was abolished by JTE-013 (Fig 4B and 4C), whereas VPC-23019 had no effect on S1P-induced inhibition of MMP2 expression and secretion (Fig 4D and 4E). To confirm these findings, the C643 cells were transfected with S1P2 siRNA. Both the mRNA and protein expression of S1P2 was efficiently downregulated (Fig 4F and 4G). As can be seen in Fig 4H and 4I, the S1P-evoked attenuation of MMP2 expression and activity was abolished by S1P2 knockdown. Surprisingly, neither VPC-23019 nor JTE-013 had an effect on the S1P-evoked effects on MMP9 (data not shown). Thus, the S1P-induced inhibition of expression and activity of MMP2 is mediated by S1P2.

MMP2 and MMP9 mediate C643 invasion

MMP2 and MMP9 are gelatinases which use collagen IV as their main substrate and regulate thyroid cancer cell invasion [13,17,18]. Recently, we have shown that blocking MMP2 and MMP9 attenuated S1P-evoked follicular ML-1 thyroid cancer cell invasion [19]. As shown above, S1P attenuated the invasion of both C643 and FTC-133 cells at 6 h and 8 h (Figs 2E and 3D). S1P also attenuated the wound healing of both C643 and FTC-133 cells (Fig 5A). This decrease in migration and invasion is not due to a decrease in proliferation, as S1P was without an effect on C643 and FTC-133 proliferation [10]. To verify the importance of MMP2 and MMP9 in C643 cell invasion, we down-regulated MMP2 and -9 with siRNA. In C643 cells transfected with siRNA against MMP2 or MMP9, basal invasion was significantly attenuated compared with control siRNA-transfected cells. However, S1P was able to significantly further inhibit invasion (Fig 5B and 5C). Next, we used either the MMP2/9 inhibitor SB-C3T (10 μM, 1 h) or double-transfection of MMP2/9 siRNA and found both treatments to significantly attenuate basal invasion of C643 cells (Fig 5D and 5E). In these experiments, S1P was again able to further attenuate invasion, showing that also other mechanisms are involved in the S1P-evoked inhibition of invasion (for a review, see [9]). The siRNA transfections caused a 60–80% knockdown of MMP2 and MMP9 expression, and S1P did not modulate their expression further (Fig 5F–5H). Knockdown of MMP2/9 also completely abolished MMP2 activity (Fig 5I). Taken together, the results clearly show that MMP2 and MMP9 participate in regulating C643 cell invasion.

S1P regulates calpain activity via S1P2 and calpain mediates S1P-induced effects on MMP2/9

Calpains are calcium-dependent endopeptidases, and in addition to many other important functions in the cell, they cleave pro-MMP2/9 to convert them into active MMP2/9. Furthermore, calpains are regulated by S1P [22]. We have recently shown that calpains are of importance in the S1P-evoked secretion of MMP2/9 in follicular thyroid cancer ML-1 cells [19]. We thus investigated the role of calpains in C643 cells. Stimulating the cells with S1P (100 nM, 6 h) attenuated calpain activity and knockdown of S1P2 with siRNA or JTE-013 abolished this...
S1P attenuates MMP2 and -9

**Figure A**

Graph showing invasion percentage for different treatments including Control, S1P (100 nM), JTE (10 μM), S1P + JTE, and VPC (1 μM). Significant differences are indicated by **.**

**Figure B**

Western blotting with β-Actin as a control for MMP2 expression and secretion. Significant differences are indicated by * and **.

**Figure C**

Western blotting for MMP2 expression with β-Actin as a control. Significant differences are indicated by **.

**Figure D**

Western blotting of MMP2 and β-Actin for different treatments including Control, S1P, VPC, and VPC+S1P. Significant differences are indicated by *.

**Figure E**

Western blotting for MMP2 expression and secretion with β-Actin as a control. Significant differences are indicated by ***.

**Figure F**

Bar graph showing mRNA expression levels for S1P2. Significant differences are indicated by ***.

**Figure G**

Western blotting of S1P2 and Hsc70 with β-Actin as a control. Significant differences are indicated by ***.

**Figure H**

Western blotting for MMP2 expression with β-Actin as a control. Significant differences are indicated by **.

**Figure I**

Western blotting for MMP2 activity. Significant differences are indicated by ** and ***.
**Fig 4.** S1P-evoked inhibition of invasion and the expression, secretion and activity of MMP2 is mediated through S1P$_2$. (A) C643 cells were pre- incubated with S1P$_2$ antagonist JTE-013 (10 μM for 1 h) or S1P$_{1,3}$ inhibitor VPC23019 (1 μM for 1 h) and allowed to invade through collagen IV towards 5% lipid-stripped FBS in the presence or absence of 100 nM S1P for 6 h. (B) C643 cells were treated with S1P$_2$ antagonist JTE-013 (10 μM for 1 h) and then stimulated with S1P (100 nM for 6 h). A representative western blot is shown. β-Actin was used as loading control and the normalized data are presented in the graph. (C) C643 cells were treated with the S1P$_2$ antagonist JTE-013 (10 μM for 1 h) and then stimulated with S1P (100 nM for 6 h), and the medium was collected. The representative western blot shows the secretion of MMP2. The data were normalized to the protein content on the plates and are presented in the graph. (D) C643 cells were treated with S1P$_{1,3}$ inhibitor VPC23019 (1 μM for 1 h) and then stimulated with S1P (100 nM for 6 h). A representative western blot is shown. β-Actin was used as loading control and the normalized data are presented in graph. (E) C643 cells were treated with S1P$_{1,3}$ inhibitor VPC23019 (1 μM for 1 h) and then stimulated with S1P (100 nM for 6 h), and the medium was collected. The representative western blot shows the secretion of MMP2. The data were normalized to the protein content on the plates and are presented in the graph. (F and G) C643 cells after 48 h transfection with S1P$_2$ siRNA. The normalized graph shows the efficient knockdown of S1P$_2$ on mRNA level and the representative western blot shows the knockdown of S1P$_2$ on protein level. (H and I) C643 cells were transfected with scrambled control siRNA or S1P$_2$ analyzed with one-way ANOVA and Bonferroni’s post hoc test (±P<0.05; *P<0.01; **P<0.001; ***P<0.0001; n=3–4). Asterisks (*) denote the statistically significant differences compared with respective control. (¤) indicates comparisons between S1P effects. Data were analyzed with one-way ANOVA and Bonferroni’s post hoc test (*P<0.05; **P<0.01; ***P<0.001; n=3–4). 

The Rho-ROCK pathway mediates S1P-induced inhibition of MMP2

Previous studies have shown that S1P through S1P$_2$ activates Rho, and that Rho in turn inhibits cell motility through activation of ROCK and inhibition of Rac [10,23,24]. Also, we have recently shown that the S1P-induced inhibition of C643 migration is mediated by the intermediate filament protein vimentin whose phosphorylation S1P induces through S1P$_2$ and ROCK [25]. In Fig 7A we show that S1P, as expected, transiently increased Rho activity in C643 cells. Pre-incubation of these cells with the Rho inhibitor C3-transferase (100 ng/ml, 4 h) or with the ROCK inhibitor Y-27632 (10 μM, 1 h) resulted in a significant increase in basal invasion. Furthermore, the S1P-induced inhibition of invasion was abolished (Fig 7B). Zymography experiments revealed that inhibition of Rho or ROCK had no significant effect on basal MMP2 activity but that the S1P-evoked decrease in MMP2 activity was abolished (Fig 7C). The Rho inhibitor had no significant effect on basal MMP2 expression. However, Rho inhibition did prevent the S1P-induced decrease in MMP2 expression (Fig 7D). When the cells were treated with the ROCK inhibitor, there was again no effect on the basal expression of MMP2, but S1P significantly increased the expression of MMP2 instead of decreasing it (Fig 7E). Taken together, these results suggest that S1P decreases MMP2 expression and activity through the S1P$_2$–Rho-ROCK pathway.

**Discussion**

S1P modulates cell invasion and migration of cancer cells, including thyroid cancer cells, by activating S1P receptors and associated down-stream signaling pathways. S1P$_{1,3}$ are pro-
S1P attenuates MMP2 and -9

A

Wound Healing Assay C643

Control 0 hour  S1P 0 hour  Control 24 hour  S1P 24 hour

Wound Healing Assay FTC-133

Control 0 hour  S1P 0 hour  Control 24 hour  S1P 24 hour

C643

0 h  24 h

% Wound

0  50  100  150

C  S1P  C  S1P  C  S1P  C  S1P

***

FTC - 133

0 h  24 h

% Wound

0  50  100  150

C  S1P  C  S1P  C  S1P  C  S1P

***

B

C

siRNA

siRNA MMP2

% Invasion

0  50  100  150

C  S1P  C  S1P  C  S1P  C  S1P

***

siRNA MMP9

% Invasion

0  50  100  150

C  S1P  C  S1P  C  S1P  C  S1P

***

C

siRNA

siRNA MMP2/9

% Invasion

0  50  100  150

C  S1P  C  S1P  C  S1P  C  S1P

***

siRNA MMP9/9

% Invasion

0  50  100  150

C  S1P  C  S1P  C  S1P  C  S1P

***

D

% Invasion

0  50  100  150

C  S1P  S1P  S1P  S1P  S1P

***

G

siRNA

siRNA MMP2/9

Relative MMP2 Expression

0.0  0.5  1.0  1.5

C  S1P  C  S1P  C  S1P

***

siRNA MMP9

Relative MMP2 Expression

0.0  0.5  1.0  1.5

C  S1P  C  S1P

***

H

siRNA

siRNA MMP9

Relative MMP2 Expression

0.0  0.5  1.0  1.5

C  S1P  C  S1P

***

I

siRNA

siRNA MMP2/9

MMP2

64 KDa

C  S1P  C  S1P

Fig 5. MMP2 and MMP9 regulate C643 invasion. (A) Wound healing assay for C643 and FTC-133 cell migration. Images were taken immediately after wound scratch at 0 h and after 24 h. The cells were stimulated with vehicle or 100 nM S1P. (B and C) C643 cells were transfected with negative control siRNA, MMP2 siRNA or with MMP9 siRNA. After 48 hours of transfection, the cells were allowed to invade through collagen IV towards 5% lipid-stripped FBS for 6 h. (D) C643 cells were pre-incubated with the MMP2/9 inhibitor SB (10 μM, 1 h) and were allowed to invade towards 5% lipid-stripped FBS for 6 hours in the presence or absence of 100 nM S1P. (E) C643 cells were transfected with negative control siRNA or with siRNA for MMP2 and -9. After 48 hours of transfection, the cells were allowed to invade towards 5% lipid-strippped FBS for 6 hours in the presence or absence of 100 nM S1P. (F) C643 cells were transfected with negative control siRNA or with siRNA for MMP2 and -9. After 48 hours of transfection, the cells were stimulated with S1P for 6 hours and the expression of MMP2 and -9 was measured. A representative western blot is shown. (G and H) C643 cells were transfected with negative control siRNA, MMP2 siRNA or MMP9 siRNA. After 48 hours of transfection, the cells were stimulated with 100 nM S1P for 6 hours and the expression of MMP2 and -9 was measured. Representative western blots are shown. β-Actin was used as loading control, and the normalized results are presented in the graphs. (I) As in (F), but the medium was collected and the activity of MMP2 measured using the zymography assay. The data were normalized to the protein content on the plates. (G and H) C643 cells were transfected with negative control siRNA, with MMP2 siRNA or MMP9 siRNA. After 48 hours of transfection, the cells were stimulated with 100 nM S1P for 6 hours and the expression of MMP2 and -9 was measured. Representative western blots are shown. β-Actin was used as loading control, and the normalized results are presented in the graphs. The normalized results in the graphs are the mean ±S.E.M, n = 3. Asterisks (*) denote the statistically significant differences compared with respective control. (†) indicates comparisons between S1P effects. Data were analyzed with one-way ANOVA and Bonferroni’s post hoc test (* P < 0.05; ** P < 0.01; *** P < 0.001; ¶ P < 0.05; ¶¶ P < 0.01; ¶¶¶ P < 0.001).

https://doi.org/10.1371/journal.pone.0196992.g005

migratory receptors which strongly couple to G_i and activate the migratory pathway [3–5,26,27], whereas S1P_2 usually functions as an anti-migratory receptor that couples strongly to G_12/13 [23,24,27,28] (but see [11]). In the present report, we show that S1P potently attenuates the expression, secretion and activity of MMP2, and to a lesser degree, the secretion and activity of MMP9. This is a novel mechanism by which the anti-migratory receptor S1P_2 can convey its effects on cells, and is, in part, a mechanism mediating the inhibitory effect of S1P_2 on invasion.

Matrix metalloproteinases (MMPs) are important regulators of cell invasion in several malignant forms of cancer [13,17]. Previous studies have indicated that MMP2 and -9 enhance invasion of thyroid cancer cells [15,16,18]. We have recently reported that S1P evokes invasion of thyroid follicular ML-1 cancer cells mainly through S1P_1 [8], and that this effect is, in part, induced by the S1P-evoked secretion and activity of MMP2 and -9 [19]. In the present study, S1P decreased consistently and significantly the expression, secretion and activity of MMP2. In contrast, S1P evoked a biphasic effect on MMP9: first, a decrease in expression, followed by an increase in expression. This finding is in line with a recent report showing that S1P, through activation of S1P_2, enhances MMP9 expression and secretion [29]. However, in our cells the secretion was transiently decreased, and the activity was attenuated during all investigated time points. This was an interesting finding, considering that the expression of MMP9 was increased after long incubations with S1P. Presently we do not have any explanation for the biphasic effect of S1P on MMP9 or for the decreased activity of the secreted MMP9. One possibility is that the increased expression is a compensatory mechanism, but that the inhibitory effect of S1P on calpain activity rendered MMP9 inactive.

It is interesting to note that the S1P receptor expression profile between the ML-1 and C643 cells is very similar. Although S1P_1 may also have a pro-migratory role in some cell types, it apparently cannot override the inhibitory effect of S1P_2 in the C643 cells. It is also worth mentioning, that normal primary thyroid cells [6] and the normal thyroid N-Thy-Ori cell line (Asghar and Törnquist, unpublished data) express these receptors, but S1P is unable to either stimulate or inhibit the invasion of these cells.

After observing the surprising time-dependent effects of S1P on the expression, secretion and activity of MMP2 and -9, we were interested in investigating if this would affect the invasive behavior of the cells. We found that S1P potently decreased invasion of the C643 cells at all time points investigated, as was also shown by us previously [10]. To corroborate our observations, we stimulated thyroid follicular FTC-133 cancer cells with S1P. In these cells, we observed similar effects of S1P on invasion and MMP2 expression, and on secretion and activity of both MMP2 and MMP9, as those observed in the C643 cells. We next investigated the
S1P attenuates MMP2 and -9
importance of MMP2 and -9 per se on the invasion of the cells, as these two MMPs are important for thyroid cancer cell invasion [15,16,18,19]. By using siRNA against MMP2 and MMP9, or by inhibiting MMP2/9 pharmacologically, we showed that the basal invasion was significantly attenuated. However, S1P was still able to further decrease the invasion. This suggests that the inhibition of invasion by S1P is not only mediated through inhibition of MMP2 and MMP9, but also through other signaling mechanisms, as has been shown previously [23,24,27,28,30,31]. The situation is quite similar to what we previously saw in follicular thyroid cancer ML-1 cells, where knock-down of MMP2 and -9 only partially inhibited the invasion in response to S1P. This result clearly suggests that not only MMP2 and -9 are important in regulating thyroid cancer cell invasion.

We have earlier reported that S1P inhibited the migration of C643 cells through activation of S1P2 [10], and thus wanted to know which S1P receptor was involved in the S1P-evoked attenuation of the MMPs. We investigated MMP2 only, as these results were more consistent. By using either the S1P2 antagonist JTE-013 or S1P2 siRNA, we showed that the inhibitory effect of S1P on expression and activity of MMP2 was abolished. S1P1,3 have been shown to increase the secretion and activity of MMP2 and MMP9 in several cancer cells [13,19]. However, inhibiting S1P1,3 was without a significant effect on the S1P-evoked expression or secretion of MMP2. Interestingly, inhibiting S1P1,3 or S1P2 was without an effect on MMP9 expression and activity, at least at the time points investigated. Thus, contrary to the report by [29], in C643 cells S1P2 has an inhibitory effect on at least MMP2 secretion and activity.

Calpains are important in regulating many cellular functions, including cell invasion, by cleaving the inactive pro-MMPs to active MMPs [32,33], and S1P has been shown to regulate calpain activity [22]. In thyroid cancer ML-1 cells, S1P was able to enhance calpain activity and MMP2 and -9 secretion, thus enhancing invasion [19]. We found that in C643 cells, S1P decreased calpain activity through S1P2. Inhibiting calpains resulted in a decreased expression and activity of MMP2 and MMP9, as well as decreased secretion of MMP2. These results are in line with previous studies [22,32,34]. Furthermore, the basal invasion was significantly attenuated; however, S1P was still able to slightly, but significantly, further attenuate invasion. This supports our conclusion that MMP2 and -9 are not the only players in S1P-evoked inhibition of invasion of these cells.

S1P2 couples to G12/13 and activates the small GTPase Rho [31]. On activation, Rho inhibits Rac, resulting in an attenuated invasion and migration. In the present investigation, S1P increased Rho activity transiently. Previously, we have reported that stimulating the cells with S1P decreased Rac activity and that incubating C643 cells with a Rac inhibitor potently decreased migration [10]. As Rac is required for activation of MMP2 [35], our observed activation of Rho (and thus inhibition of Rac) probably, in part, explains the decreased activation of MMP2. Furthermore, pharmacological inhibition of either Rho or ROCK, slightly, but
significantly, enhanced invasion of C643 cells. Similar findings were observed in mesenchymal stromal cells, where treatment of cells with either C3-transferase or Y27632 enhanced the migration towards serum [36]. Interestingly, no significant change was, however, observed on the basal expression of MMP2 and -9 in these cells, but the S1P-evoked decrease in the expression and activity of MMP2 was inhibited. Thus, the Rho pathway is important for the regulation of at least MMP2.

We conclude that the S1P regulates the expression, secretion and activity of MMP2 and MMP9. This, in part, attenuates C643 cancer cell invasion. Our data introduces a new mechanism by which S1P, through activation of S1P2, can attenuate invasion and migration of cancer cells. Our results thus broaden the palette by which S1P or its analogs can be used to curtail the invasive and metastatic behavior of cancer cells.

Acknowledgments

This study was financially supported by the Sigrid Juselius Foundation, the Oskar Öflund Foundation, the Ida Montin Foundation and the Finnish-Norwegian Medical Foundation, which is gratefully acknowledged.

Author Contributions

Conceptualization: Kid Törnquist.
Data curation: Muhammad Yasir Asghar, Kati Kemppainen.
Formal analysis: Kid Törnquist.
Funding acquisition: Muhammad Yasir Asghar, Kid Törnquist.
Investigation: Muhammad Yasir Asghar, Kati Kemppainen, Taru Lassila.
Methodology: Kati Kemppainen.
Project administration: Kid Törnquist.
Supervision: Kid Törnquist.
Writing – original draft: Muhammad Yasir Asghar, Kid Törnquist.
Writing – review & editing: Muhammad Yasir Asghar, Kid Törnquist.

References

1. Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat Rev Cancer. 2010; 10: 489–503. https://doi.org/10.1038/nrc2875 PMID: 20555359
2. Spiegel S, English D, Milstien S. Sphingosine 1-phosphate signaling: providing cells with a sense of direction. Trends Cell Biol. 2002; 12: 236–242. PMID: 12062172
3. Windh RT, Lee MJ, Hia T, An S, Barr AJ, Manning DR. Differential coupling of the sphingosine 1-phosphate receptors Edg-1, Edg-3, and H218/Edg-5 to the G(i), G(q), and G(12) families of heterotrimeric G proteins. J Biol Chem. 1999; 274: 27351–27358. PMID: 10488065

4. Okamoto H, Takuwa N, Yokomizo T, Sugimoto N, Sakurada S, Shigematsu H, et al. Inhibitory regulation of Rac activation, membrane ruffling, and cell migration by the G protein-coupled sphingosine-1-phosphate receptor EDG5 but not EDG1 or EDG3. Mol Cell Biol. 2000; 20: 9247–9261. PMID: 11094076

5. Taha TA, Argraves KM, Obeid LM. Sphingosine-1-phosphate receptors: receptor specificity versus functional redundancy. Biochim Biophys Acta. 2004; 1682: 48–55. https://doi.org/10.1016/j.bbalip.2004.01.006 PMID: 15158755

6. Balthasar S, Samulin J, Ahlgren H, Bergelin N, Lundqvist M, Toescu EC, et al. Sphingosine 1-phosphate receptor expression profile and regulation of migration in human thyroid cancer cells Biochern J. 2006; 398: 547–556. https://doi.org/10.1042/BJ20060299 PMID: 16753042

7. Balthasar S, Bergelin N, Lof C, Vainio M, Andersson S, Tornquist K. Interactions between sphingosine-1-phosphate and vascular endothelial growth factor signalling in ML-1 follicular thyroid carcinoma cells. Endocr Relat Cancer. 2008; 15: 521–534. https://doi.org/10.1677/ERC-07-0253 PMID: 18509004

8. Bergelin N, Lof C, Balthasar S, Kalhori V, Tornquist K, and VEGFR-2 form a signaling complex with extracellular regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration. Endocrinology. 2010; 151: 2994–3005. https://doi.org/10.1210/en.2009-1387 PMID: 20501673

9. Skoura A, Hia T. Regulation of vascular physiology and pathology by the S1P2 receptor subtype. Cardiovasc Res. 2009; 82: 221–228. https://doi.org/10.1093/cvr/cvp088 PMID: 19287048

10. Asghar MY, Viitanen T, Kemppainen K, Tornquist K. Sphingosine 1-phosphate and human ether-a-go-go-related gene potassium channels modulate migration in human anaplastic thyroid cancer cells. Endocr Relat Cancer. 2012; 19: 667–680. https://doi.org/10.1530/ERC-12-0092 PMID: 22889737

11. Patmanathan SN, Johnson SP, Lao SL, Panja Bernam S, Lopes v, Wei W, et al. Aberrant expression of the S1P regulating enzyme, SPHK1 and SGPL1, contributes to migratory phenotype in OSCC mediated through S1PR2. Sci Rep. 2016, https://doi.org/10.1038/srep25650

12. Marei H, Carpy A, Woroniuk A, Vennin C, White G, Timpson P, et al. Differential Rac1 signalling by guanine nucleotide exchange factors implicates FLII in regulating Rac1-driven cell migration. Nat Commun. 2016; 7: 10664. https://doi.org/10.1038/ncomms10664 PMID: 26887924

13. Devine K, Smicun Y, Hope J, Fishman D. S1P induced changes in epithelial ovarian cancer proteolysis, invasion, and attachment care mediated by Gi and Rac. Gynecol Oncol. 2008; 110: 237–245. https://doi.org/10.1016/j.ygyno.2008.04.013 PMID: 18513786

14. Nabeshima K, Inoue T, Shimao Y, Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int. 2002; 52: 255–264. PMID: 12031080

15. Yang Q, Ji M, Guan H, Shi B, Hou P. Shikonin inhibits thyroid cancer cell growth and invasiveness through targeting major signaling pathways. J Clin Endocrinol Metab. 2013; 98: E1909–17. https://doi.org/10.1210/jc.2013-2583 PMID: 24106286

16. Zhang X, Lux, Jiao X, Chen B, Wu J. PLK1 gene suppresses cell invasion of undifferentiated thyroid carcinoma through the inhibition of CD44v6, MMP-2 and MMP-9. Exp Ther Med. 2012; 4: 1005–1009. https://doi.org/10.3892/etm.2012.729 PMID: 23226764

17. Kim ES, Kim JS, Kim SG, Hwang S, Lee CH, Moon A. Sphingosine 1-phosphate regulates metalloproteinase-9 expression and breast cell invasion through S1P3-Galphaq coupling. J Cell Sci. 2011; 124: 2220–2230. https://doi.org/10.1242/jcs.076794 PMID: 21652634

18. Rajoria S, Suriano R, George A, Schantz P, Geliebter J, Tiwari R. Estrogen Induced Metastatic Modulators MMP-2 and MMP-9 Are Targets of 3,3′-Diindolylmethane in Thyroid Cancer. PLoS One. 2011; Jan 18; 6(1):e15879. https://doi.org/10.1371/journal.pone.0015879 PMID: 21267453

19. Kalhori V, Tornquist K. MMP2 and MMP9 participate in S1P-induced invasion of follicular ML-1 thyroid cancer cells. Mol Cell Endocrinol. 2015; 404:113–122. https://doi.org/10.1016/j.mce.2015.01.037 PMID: 25643979

20. Schweppes RE, Klopper JP, Korch C, Pugazhenthhi U, Benezra M, Knauf JA, et al. Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. J Clin Endocrinol Metab. 2008; 93: 4331–4341. https://doi.org/10.1210/jc.2008-1102 PMID: 18713817

21. Bergelin N, Lof C, Balthasar S, Kalhori V, Tornquist K. S1P1 and VEGFR-2 form a signaling complex with extracellularly regulated kinase 1/2 and protein kinase C-alpha regulating ML-1 thyroid carcinoma cell migration. Endocrinology. 2010; 151: 2994–3005. https://doi.org/10.1210/en.2009-1387 PMID: 20501673
22. Kang H, Kwak HI, Kaunas R, Bayless KJ. Fluid shear stress and sphingosine 1-phosphate activate calpain to promote membrane type 1 matrix metalloproteinase (MT1-MMP) membrane translocation and endothelial invasion into three-dimensional collagen matrices. J Biol Chem. 2011; 286: 42017–42026. https://doi.org/10.1074/jbc.M111.290841 PMID: 22002053

23. Takuwa N, Du W, Kaneko E, Okamoto Y, Yoshioka K, Takuwa Y. Tumor-suppressive sphingosine-1-phosphate receptor-2 counteracting tumor-promoting sphingosine-1-phosphate receptor-1 and sphingosine kinase 1—Jekyll Hidden behind Hyde Am J Cancer Res. 2011; 1: 460–481. PMID: 21984966

24. Witt W, Jannasch A, Burkhard D, Christ T, Ravens U, Brunssen C, et al. Sphingosine-1-phosphate induces contraction of valvular interstitial cells from porcine aortic valves. Cardiovasc Res. 2012; 93: 490–497. https://doi.org/10.1093/cvr/cvs002 PMID: 2232739

25. Hyder CL, Kemppainen K, Isoniemi KO, Imanishi SY, Goto H, Inagaki M, et al. Sphingolipids inhibit vimentin-dependent cell migration. J Cell Sci. 2015; 128: 2057–2069. https://doi.org/10.1242/jcs.160341 PMID: 25908861

26. Gonda K, Okamoto H, Takuwa N, Yatomi Y, Okazaki H, Sakurai T, et al. The novel sphingosine 1-phosphate receptor AGR16 is coupled via pertussis toxin-sensitive and-insensitive G-proteins to multiple signalling pathways. Biochem J. 1999; 337 (Pt 1): 67–75.

27. Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA, et al. Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/LP (B2)/EDG-5 and S1P(3)/LP(B3)/EDG-3. J Biol Chem. 2002; 277: 25152–25159. https://doi.org/10.1074/jbc.M100137200 PMID: 12006579

28. Hashimoto M, Wang X, Mao L, Kobayashi T, Kawasaki S, Mori N, et al. Sphingosine-1-phosphate potentiates human lung fibroblast chemotaxis through the S1P2 receptor. Am J Respir Cell Mol Biol. 2008; 39: 356–363. https://doi.org/10.1165/rccm.2006-0427OC PMID: 18367729

29. Bi Y, Li J, Ji B, Kang N, Yang L, Simonetto DA, et al. Sphingosine-1-phosphate mediates a reciprocal signaling pathway between stellate cells and cancer cells that promotes pancreatic cancer growth. Am J Pathol. 2014; 184: 2791–2802. https://doi.org/10.1016/j.ajpath.2014.06.023 PMID: 25111230

30. Takashima S, Sugimoto N, Takuwa N, Okamoto Y, Yoshioka K, Takamura M, et al. G12/13 and Gq mediate S1P2-induced inhibition of Rac and migration in vascular smooth muscle in a manner dependent on Rho but not Rho kinase. Cardiovasc Res. 2008; 79: 689–697. https://doi.org/10.1093/cvr/cvn118 PMID: 18480127

31. Lepley D, Paik JH, Hla T, Ferrer F. The G protein-coupled receptor S1P2 regulates Rho/Rho kinase pathway to inhibit tumor cell migration. Cancer Res. 2005; 65: 3788–3785. https://doi.org/10.1158/0008-5472.CAN-04-2311 PMID: 15867375

32. Storr SJ, Carragher NO, Frame MC, Parr T, Martin SG. The calpain system and cancer. Nat Rev Cancer. 2011; 11: 364–374. https://doi.org/10.1038/nrc3050 PMID: 21508973

33. Storr SJ, Thompson N, Pu X, Zhang Y, Martin SG. Calpain in Breast Cancer: Role in Disease Progression and Treatment Response. Pathobiology. 2015; 82: 133–141. https://doi.org/10.1159/000430464 PMID: 26330354

34. Kwak HI, Kang H, Dave JM, Mendoza EA, Su SC, Maxwell SA, et al. Calpain-mediated vimentin cleavage occurs upstream of MT1-MMP membrane translocation to facilitate endothelial sprout initiation. Angiogenesis. 2012; 15: 287–303. https://doi.org/10.1007/s10456-012-9262-4 PMID: 22407449

35. Zhuge Y, Xu J. Rac1 mediates type I collagen-dependent MMP-2 activation, role in cell invasion across collagen barrier. J Biol Chem. 2001; 276: 16248–16256. PMID: 11340084

36. Jagannathan BG, Ruester B, Dressel L, Stein S, Grez M, Seifried E, et al. Rho inhibition induces migration of mesenchymal stromal cells. Stem Cells. 2007; 25: 1966–1974. https://doi.org/10.1634/stemcells.2007-0167 PMID: 17510214